Ryan White Care Hepatitis C & B Language
NATAP Webinars
View all archived NATAP webinars here
Current HIV Articles and News Updates
HIV
Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel
- (12/30/24)
Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection
- (12/23/24)
New HHS ART Guidelines discuss & Provide Guidance: Immunologc Aging, Bone Screening, Frailty, Cognitive Evaluations, Polypharmacy, DDIs in Older PWH
- (12/19/24)
More HIV Articles...
Hepatitis D
HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
- (12/18/24)
AASLD:
CHARACTERIZATION OF THE DIRECT ANTIVIRAL EFFECT OF REP 2139 IN 2D AND 3D HDV INFECTION MODELS
- (12/11/24)
AASLD:
Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis Delta Receiving Bulevirtide With or Without Pegylated Interferon Alfa-2a in MYR204
- (12/04/24)
AASLD:
HBV/HDV Genotypes in HBV/HDV-Coinfected Patients in the United States
- (12/04/24)
More Hep D Articles...
Aging & Perinatally Acquired HIV
Weight Gain After Antiretroviral Therapy Initiation and Subsequent Risk of Metabolic and Cardiovascular Disease
- (12/31/24)
INSTI & Diabetes Risk - 3 studies
- (12/31/24)
Lessons Learned from a Community-led, Pilot Teletherapy Group for Older Women Living with Depression and HIV
- (12/23/24)
More Aging & HIV Articles...
PrEP
HIVR4P
ACCEPTABILITY OF AN ON-DEMAND, SINGLE-DOSE TENOFOVIR RECTAL DOUCHE FOR HIV PRE-EXPOSURE PROPHYLAXIS IN YOUNG MEN (ATN 163)
- (12/24/24)
Trends in Oral and Injectable HIV Preexposure Prophylaxis Prescriptions in the US, 2013-2023
- (12/20/24)
CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024
- (12/20/24)
More PreP Articles...
Current Hepatitis C and B Articles
Hepatitis C
Racial and Ethnic Disparities in Hepatitis C Care in Reproductive-Aged Women With Opioid Use Disorder: 10% HCV treatment rates; African-Americans 25% less likely to be screened
- (12/28/24)
CDC and SAMHSA Leaders Encourage HIV and Viral Hepatitis Testing in Substance Use Disorder Treatment
- (12/28/24)
Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
- (12/11/24)
AASLD:
Bemnifosbuvir Does Not Alter Cardiac Repolarization in Healthy Participants: Results from a Thorough QT Study
- (12/11/24)
AASLD:
Multiscale modeling of lead-in results from a phase 2 study of an 8-week combination regimen of Bemnifosbuvir and Ruzasvir in patients with chronic hepatitis C virus infection
- (12/11/24)
AASLD:
Bemnifosbuvir Poses High Barrier for Resistance in Both Preclinical and Phase 1b Monotherapy Studies
- (12/11/24)
More Hep C Articles...
Hepatitis B
HBV Patient Declaration of Rights
-
What will it take to cure hepatitis B? therapies in research
- (12/16/24)
Pathway to global elimination of hepatitis B: HBV cure is just the first step
- (12/16/24)
Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies
- (12/16/24)
More Hep B Articles...
Fatty Liver, NAFLD, NASH
AASLD:
HIGH PREVALENCE AND LOW AWARENESS OF CHRONIC LIVER DISEASE AMONG SEXUAL MINORITY MEN IN LOS ANGELES
- (12/04/24)
AASLD:
Akero Therapeutics to Showcase New Analyses of Phase 2b [efruxifermin] HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
- (12/04/24)
AASLD:
Efruxifermin significantly reduced proportion of participants with at-risk MASH and led to near-complete histological disease reversal at week 96 in the HARMONY study
- (12/04/24)
AASLD:
Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting 2024
- (12/04/24)
AASLD:
Resmetirom effects on NASH with liver fibrosis in patients with NASH genetic risk alleles
- (12/04/24)
AASLD:
Effect of Resmetirom or Placebo in NASH Fibrosis Patients With <5% or ≥5% Weight Loss and/or on Baseline GLP-1 Therapy in the MAESTRO-NASH 52-Week Serial Liver Biopsy Study
- (12/04/24)
AASLD:
SEVEN-YEAR FOLLOW-UP OF A PREDOMINANTLY HISPANIC PATIENTS WITH SIGNIFICANT STEATOSIS AT A PRIMARY CARE CLINIC: UPDATE ON THE SOUTH BAY COHORT
- (12/04/24)
More Fatty Liver Articles...
Check Out Our Special NATAP Features
List not necessarily listed here in order of date being held.
https://academicmedicaleducation.com/meeting/2nd-african-workshop-women-hiv-2025
https://academicmedicaleducation.com/meeting/2nd-menopause-hiv-webinar-2025
https://www.croiconference.org
https://academicmedicaleducation.com/meeting/15th-international-workshop-women-hiv-2025
https://acthiv.org/
https://ddw.org/
https://www.easlcongress.eu/
https://asm.org/Events/ASM-Microbe/Home
IAS 2025, the 13th IAS Conference on HIV Science,
Kigali, Rwanda, July 13 to 17,
pre-conferences on 13 July.
https://www.iasociety.org/conferences/ias2025
https://academicmedicaleducation.com/meeting/26th-international-workshop-clinical-pharmacology-hiv-hepatitis-and-other-antiviral-drugs
https://academicmedicaleducation.com/meeting/11th-international-viral-hepatitis-elimination-meeting-ivhem-2025
https://academicmedicaleducation.com/meeting/8th-conference-liver-disease-africa-colda-2025
https://www.eacsociety.org/european-aids-conference/european-aids-conference/
https://idweek.org/
https://academicmedicaleducation.com/meeting/16th-international-workshop-hiv-aging-2025
https://www.aasld.org/the-liver-meeting
https://neurohiv.com/
